{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:05Z","timestamp":1790736665574,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>WHIM syndrome (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis, or WHIMs) is a very rare autosomal dominant immunodeficiency disorder attributable to mutations in <jats:italic toggle=\"yes\">CXCR4<\/jats:italic>. We reviewed clinical manifestations in 24 patients in 9 families to expand understanding of this syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Warts, cellulitis and respiratory infections are common in patients with WHIMs. Less commonly these patients have congenital heart disease, human papilloma virus-associated malignancies (cervical and vulvular) and lymphomas. Hearing loss because of recurrent otitis media is another important complication. Treatment with granulocyte colony-stimulating factor is controversial; this review indicates that it is effective to prevent and treat infections based upon long-term observations of patients enrolled in the Severe Chronic Neutropenia International Registry. Understanding the natural history and diversity of this syndrome are important for ongoing clinical trials of novel agents to treat WHIMs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>WHIM syndrome has diverse manifestations; some features occur consistently in almost all patients, for example, neutropenia, lymphocytopenia and mild hypogammaglobulinemia. However, the clinical consequences are quite variable across patient cohorts and within families. Each complication is important as a cause for morbidity and a source for patient and family concerns.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000554","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T16:04:10Z","timestamp":1572019450000},"page":"11-17","source":"Crossref","is-referenced-by-count":15,"title":["Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome"],"prefix":"10.1097","volume":"27","author":[{"given":"David C.","family":"Dale","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Dick","sequence":"additional","affiliation":[{"name":"University of Washington, Severe Chronic Neutropenia International Registry, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merideth","family":"Kelley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahagn","family":"Makaryan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Connelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Anna","family":"Bolyard","sequence":"additional","affiliation":[{"name":"University of Washington, Severe Chronic Neutropenia International Registry, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM196404022701402","article-title":"Myelokathexis\u2019--a new form of chronic granulocytopenia. Report of a case","volume":"270","author":"Zuelzer","year":"1964","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM196405072701902","article-title":"Chronic idiopathic granulocytopenia","volume":"270","author":"Krill","year":"1964","journal-title":"N Engl J Med"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat Genet"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00043426-199709000-00007","article-title":"Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature","volume":"19","author":"Hord","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9","article-title":"WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies","volume":"91","author":"Gorlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-7-71","article-title":"Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry","volume":"7","author":"Beaussant Cohen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.12574","article-title":"Genetics on a WHIM","volume":"164","author":"Al Ustwani","year":"2014","journal-title":"Br J Haematol"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2017-02-708552","article-title":"How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome","volume":"130","author":"Badolato","year":"2017","journal-title":"Blood"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/21678707.2017.1375403","article-title":"Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency","volume":"5","author":"Heusinkveld","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2019.01.045","article-title":"Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies","volume":"7","author":"Dotta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ijms20010003","article-title":"Adaptive immunodeficiency in WHIM syndrome","volume":"20","author":"Majumdar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/blood.V95.1.320","article-title":"Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors","volume":"95","author":"Aprikyan","year":"2000","journal-title":"Blood"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood-2011-06-360586","article-title":"The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome","volume":"118","author":"Dale","year":"2011","journal-title":"Blood"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2011-07-368084","article-title":"The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome","volume":"118","author":"McDermott","year":"2011","journal-title":"Blood"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2013-09-527226","article-title":"A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor","volume":"123","author":"McDermott","year":"2014","journal-title":"Blood"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the treatment of WHIM syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/SCT.2006.n.020","article-title":"The Severe Chronic Neutropenia International Registry: 10-year follow-up report","volume":"3","author":"Dale","year":"2006","journal-title":"Support Cancer Ther"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa0805051","article-title":"A syndrome with congenital neutropenia and mutations in G6PC3","volume":"360","author":"Boztug","year":"2009","journal-title":"N Engl J Med"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ejhg.2010.136","article-title":"Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3","volume":"19","author":"Banka","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/21678707.2017.1375403","article-title":"Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency","volume":"5","author":"Heusinkveld","year":"2017","journal-title":"Expert Opin Orphan Drugs"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T05:36:04Z","timestamp":1694928964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000554","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}